Document:

Prepared by R.R. Donnelley Financial -- Employment Agreement Brain K. Hutchison

 Exhibit 10.36 
  
 EMPLOYMENT AGREEMENT 
  
 This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into
on November 30, 2001, by and between REGENERATION TECHNOLOGIES, INC. (“Regeneration Technologies”), a Delaware corporation having its principal address at 2 Innovation Drive, Alachua, Florida 32615 and Brian K. Hutchison
(“Executive”). Regeneration Technologies and the Executive are collectively referred to as the “Parties” throughout this Agreement. For purposes of this Agreement, Regeneration Technologies includes any and all of its
subsidiaries, affiliates, and any other company or entity owned and/or operated in whole or in part by any officer or director of Regeneration Technologies. 
  
 INTRODUCTION 
  
 Regeneration Technologies operates a tissue processing/manufacturing
facility and desires to employ the Executive. The Executive desires to accept employment during the term of this Agreement upon the terms and conditions in this Agreement. 
  
 In consideration of the covenants, mutual promises, representations, and understandings in this Agreement, the Parties agree as follows: 
  
 1.    EMPLOYMENT. 
  
 Regeneration Technologies agrees to employ or continue to employ the Executive and the Executive agrees to accept employment or to continue in the employment of Regeneration Technologies. Executive shall be the President and Chief Executive
Officer of Regeneration Technologies during the term of this Agreement, and it is anticipated that he will also serve on the Board of Directors of Regeneration Technologies, subject to his approval for such post by the shareholders of the Company.
The duties of the Executive shall be those of a Chief Executive Officer, subject to the directions and control of Regeneration Technologies’ Board of Directors, in conjunction with Executive, from time to time and as needed. 

 
 2.    TERM OF AGREEMENT. 
  
 This Agreement shall become effective as of the date first written above, and shall cover the period of employment commencing on December 1, 2001, to November 30, 2004, unless this Agreement is terminated earlier as
hereinafter provided. This Agreement shall automatically renew for successive one (1) year periods unless either party gives written notice of his or its intent not to renew this Agreement at least sixty days prior to the expiration of the
then-current term of this Agreement. 
  
 3.    COMPENSATION 
  
 a.    Annual Salary. 
  
 Regeneration
Technologies shall pay to the Executive as compensation for the Executive’s services $13,461.53 computed bi-weekly from an annual figure of $350,000 for the first two (2) years of this Agreement, payable in accordance with the standard payroll
policies of Regeneration Technologies. Thereafter, the Executive’s salary shall be reviewed annually by Regeneration Technologies’ Board of Directors. 
  
 

 
Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K. Hutchison 
 Page 2 
  
 b.    Performance Bonus. 
  
 To provide a greater incentive for the Executive, a cash bonus shall be paid to the Executive during the first calendar quarter of each year of this Agreement, commencing in 2003, and based upon the performance of
Regeneration Technologies and the performance of the Executive during the preceding year; provided, however, that the payment of any such bonus and the amount shall be within the sole discretion of Regeneration Technologies’ Board of Directors,
subject to the following limitations on discretion. Bonuses for all years of this Agreement shall be guided by the achievement of mutually agreed upon Company plans and targets, which plans and targets shall be developed for 2002 on or before
January 31, 2002, and, thereafter, at least annually on or before February 28 of each year. In the event that Executive meets the agreed upon Company plans and targets for any given year, then his bonus shall be at least 60% of his base salary, with
the expectation that he will receive additional bonus compensation for any improvements above target, up to a maximum of an additional 40% of base salary. 
  
 c.    Stock Options. 
  
 Sign-On Stock Options:  The
Executive shall be granted options to purchase shares of common stock of Regeneration Technologies, Inc. in the amount of 500,000 shares at an exercise price based on the fair market value at the close of business on December 3, 2001, subject to
such vesting and other requirements as are set forth herein and in the Omnibus Stock Plan, the Employee Restricted Stock Agreement and the Incentive Stock Option Grant Agreement between Regeneration Technologies and the Executive as additional
consideration for services rendered to Regeneration Technologies. 
  
 Additional Stock Options:  In addition to
the stock options identified in the preceding paragraph, Executive shall be eligible to receive at least the following number of stock options for each year of this Agreement: for 2002, at least 200,000 shares, awarded during the first quarter of
2003; for 2003 at least 200,000 shares, awarded during the first quarter of 2004; for 2004 at least 100,000 shares, awarded during the first quarter of 2005. Each stock option grant referenced in this subparagraph shall be contingent upon the
Executive meeting the mutually agreed upon plan and targets for that year on the performance of the Executive and of Regeneration Technologies relative to mutually agreed upon Company plans and targets. In the event that the 500,000 additional
option shares referenced in this subparagraph are not awarded by the end of the initial term of this Agreement, then they shall remain available to Executive for at least an additional three (3) years, provided the Executive remains an active
employee of Regeneration Technologies, Inc. 
  
 d.    Business Expenses. 
  
 Except as otherwise provided in this Agreement, Regeneration Technologies shall pay, either directly or by reimbursement to the Executive, such
reasonable and necessary business expenses incurred by the Executive in the course of his employment by Regeneration Technologies as are consistent with Regeneration Technologies’ policies in existence from time to time, subject to such dollar
limitations and verification and record keeping requirements as may be established from time to time by Regeneration Technologies. 
  
 e.    Sign-On Bonus. 
  
 Regeneration Technologies shall pay Executive a one-time sign-on bonus
“grossed-up” to equal $35,000, after deductions for all applicable taxes and charges, on or before February 28, 2002. 
 

 Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K. Hutchison 
 Page
3 
  
 f.    Temporary Housing and Moving Expenses. 
  
 Regeneration Technologies will reimburse or advance all reasonable and necessary costs and expenses associated with the relocation of Executive and his
family from New Jersey to the Alachua or Gainesville, Florida area. Such reimbursements will take into account the tax consequences of any non-deductible monies, such that all reimbursements or items of imputed income will also include monies
sufficient to cover the state and federal tax liabilities associated with such payments (i.e., these payments will be “grossed-up”), and such reimbursements shall be made within thirty (30) days of the presentment of invoices for
same. 
  
 During the transition period of Executive’s move from New Jersey to Florida, Regeneration Technologies shall also
provide, for a period of up to one (1) year from December 1, 2001, the following temporary housing and travel reimbursements and advances: (i) housing in the Gainesville area at a cost of approximately $1,500 per month; (ii) one (1) round-trip
airfare for either Executive or each of Executive’s wife and children, between Gainesville and New Jersey, every weekend until July 1, 2002, then every other weekend until November 30, 2002; and (iii) one (1) all-expenses paid house-hunting
trip for Executive and his family for up to three (3) days. 
  
 g.    Key Person Life Insurance.

  
 During the term of this Agreement, Regeneration Technologies will provide, at its own expense, a “Key Person” life
insurance policy with at least a one million dollar ($1,000,000) death benefit payable to the beneficiary(ies) of Executive’s choosing. 
  
 h.    Matching Contributions to The Company’s Defined Contribution Plan. 
  
 Regeneration Technologies shall match all of Executive’s contributions to the Company’s 401(k) retirement plan, on a dollar for dollar basis, up to six percent (6%) of Executive’s salary, but only to the maximum excludable
dollar amount permitted by the then-current applicable Internal Revenue Code and Regulations for qualified plans. In addition, Executive will be able to participate in any non-qualified retirement plans established for highly compensated employees,
as of the date of the establishment of any such plans. 
  
 i.    Employee Benefits. 

 
 The Executive shall be entitled to such vacation days, sick days, insurance and other employee benefit programs as are established for all
other key executives of Regeneration Technologies, on the same basis as such other key executives are entitled thereto. It is understood that the establishment, change or termination of any such employee benefit programs is within the sole
discretion of Regeneration Technologies and that any such termination or change in any such program shall not affect this Agreement. In addition to the employee benefits provided to all other similarly situated employees, Regeneration Technologies
shall pay 100% of the premiums for Company-provided health and dental plans, the cost of an Executive Physical at least annually and financial consulting services for Executive of up to $1,000 per annum. 
  
 4.    DEVOTION TO EMPLOYMENT. 
  
 During the term of this Agreement, the Executive shall devote his full time to Regeneration Technologies and the Executive shall not engage in any other gainful employment without the written consent of Regeneration Technologies. Nothing in
this Agreement shall prohibit the Executive, however, from investing or trading in stocks, bonds, commodities, or other forms of investments in other companies or entities so long as such investments shall not constitute a conflict of interest.

 

 Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K. Hutchison 
 Page
4 
  
 5.    TERMINATION OF EMPLOYMENT. 
  
 a.    Voluntary Termination. 
  
 Either
the Executive or Regeneration Technologies may voluntarily terminate the Executive’s employment with Regeneration Technologies at any time, by delivering to the other party written notice of such intention not less than thirty (30) days prior
to the effective date of termination. In the event that Executive voluntarily terminates this Agreement, he shall be entitled only to his vested and accrued salary and other benefits otherwise due him through his last day on payroll. In the event
that Regeneration Technologies, Inc. terminates Executive’s employment for any reason other than for “Cause” (as set forth in Section b below), then Regeneration Technologies, Inc., shall pay to Executive his regular salary, and the
cash value of health, welfare and 401(k) contributions ordinarily made by Regeneration Technologies, Inc., on Executive’s behalf, for the payout period. In the case of termination within the first year of this Contract the payout period shall
be for the remainder of the first year and an additional year and five (5) days; otherwise, the payout period shall be for a period of one year from the date of termination of Executive’s employment. Executive shall also continue to vest during
the payout period in all previously granted stock options then outstanding. Executive shall not be entitled to accrue additional unearned bonuses or stock options for the payout period. 
  
 b.    Termination For Cause. 
  
 Regeneration Technologies may immediately terminate the Executive’s employment (and, except as otherwise specifically provided hereunder, this Agreement) for cause by giving written notice (without regard to the thirty (30) day notice
period provided in paragraph a above) of such termination to Executive specifying the grounds therefor. The decision to terminate Executive’s employment for cause shall be made at the sole discretion of the Board of Directors of Regeneration
Technologies. A termination for cause shall consist of one or more of the following events: 
  

	 	(1)
	 
	The conviction of a felony involving theft, fraud, or embezzlement; 
 

  

	 	(ii)
	 
	Deliberate and continuous neglect of Executive’s duties as an employee and executive of Regeneration Technologies, but only after notice to Executive of such dereliction
of duty, and an opportunity to cure of at least thirty (30) days; or 
 

  

	 	(iii)
	 
	Violating the covenants set forth in Paragraphs 6, 7, 9, 10 and 11 of this Agreement. 
 

  
 c.    Termination Upon Death, Incompetency, or Disability. 
  
 Regeneration Technologies shall have the right to terminate the Executive’s employment with Regeneration Technologies (and, except as otherwise specifically provided hereunder, this Agreement) immediately and
without prior written notice to the Executive as required by paragraph “a” above in the event that the Executive dies, is adjudicated incompetent, or is permanently disabled, as defined by this Agreement. In this Agreement, the term
permanently disabled shall mean that the Executive is unable to perform adequately his or her regular duties under this Agreement as a result of sickness or accident and such disability condition appears to be permanent. The determination of
permanent disability shall be made at the sole discretion of Regeneration Technologies’ Board of Directors and such a determination shall be final and binding on the Executive. 
 

 Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K. Hutchison 
 Page
5 
 6.    CONFIDENTIAL INFORMATION AND INTELLECTUAL PROPERTY. 
  
 The Executive acknowledges, recognizes and understands that, in connection with the Executive’s employment with Regeneration Technologies, the Executive has and will have access to certain proprietary, sensitive
and confidential information of Regeneration Technologies including but not limited to: the identity of Regeneration Technologies’ clients, prospective clients, and other client information; the existence of negotiations with prospective
clients of Regeneration Technologies; marketing data and plans; financial information and financial data not publicly disclosed; all drawings, records, sketches, and models; trade secrets and trade secrets relating to services of Regeneration
Technologies; and, products sold or being developed by Regeneration Technologies (“Confidential Information”). 
  
 Executive also acknowledges, recognizes and understands that Regeneration Technologies owns or has access to various types of intellectual property that are protected or may be protected by copyright, trademark, patent, trade secret, or
other laws. The types of intellectual property that are considered proprietary to Regeneration Technologies and that must be protected include but are not limited to: patent applications; trademarks; programs; source and relocatable code for all
programs; engineering, research, and technical documents; unpublished product specifications; products sold or under development; and, information belonging to other companies that is provided to Regeneration Technologies under confidentiality
agreements (“Intellectual Property”). 
  
 The Executive acknowledges and agrees that the maintenance of the
confidentiality of the Confidential Information and Intellectual Property and restrictions on the use of the Confidential Information and Intellectual Property is essential to Regeneration Technologies. The provisions of this Paragraph 6 shall
survive the termination of Executive’s employment with Regeneration Technologies. 
  
 7.    NON-DISCLOSURE OF CONFIDENTIAL
INFORMATION AND INTELLECTUAL PROPERTY. 
  
 The Executive shall not, during or after the termination of his or her
employment with Regeneration Technologies: (a) directly or indirectly publish, disclose, reproduce, record, make facsimiles of, abstract, summarize, remove, make accessible, or misappropriate any Confidential Information or Intellectual Property as
defined under this Agreement, to any person (including family members and friends), firm, corporation, or association or other entity, competitor or third party, for any reason whatsoever; or, (b) use, keep, or otherwise deal in or with such
Confidential Information or Trade Secrets, except during employment with Regeneration Technologies and for the benefit of Regeneration Technologies, without prior written permission of the Board of Directors of Regeneration Technologies. The
Executive agrees not to disclose any Confidential Information or Intellectual Property’ to other employees of Regeneration Technologies or to any third parties, except on a need to know basis for the benefit of Regeneration Technologies or as
authorized by the Board of Directors of Regeneration Technologies. 
  
 All of the Confidential Information or Intellectual Property
listed in Paragraph number six (6) above is, and shall remain, the exclusive property of Regeneration Technologies, and shall not be removed from Regeneration Technologies’ premises, without the prior written consent of the Board of Directors
of Regeneration Technologies. The Executive shall return all tangible items containing Confidential Information and Intellectual Property described in Paragraph number six (6) prior to or at the termination of his or her employment with Regeneration
Technologies. The Executive agrees that he is under no obligation to any former employer which is in any way inconsistent with this Agreement or which imposes any restriction on Regeneration Technologies or the Executive. The Executive also
acknowledges that he has been instructed by Regeneration Technologies that
 
 

 Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K Hutchison 
 Page 6

 during his or her employment with Regeneration Technologies, he is not to divulge to Regeneration Technologies, its employees, or its consultants, any confidential information or
intellectual property obtained by the Executive from any previous employers, entities, or persons. The provisions of this Paragraph 7 shall survive the termination of Executive’s employment with Regeneration Technologies and the termination of
this Agreement. 
  
 8.    IRREPARABLE HARM. 
  
 The Executive acknowledges and agrees that any disclosure of Confidential Information and Intellectual Property delineated in paragraph number six (6) by the Executive would cause severe
and irreparable harm to Regeneration Technologies. In the event there is a breach or a threatened breach by the Executive of the Non-Disclosure provisions of this Agreement, Regeneration Technologies shall be entitled to an injunction restraining
the Executive from disclosing, in whole or in part, such Confidential Information and Intellectual Property or from rendering a service to any person, firm, corporation, association, or other entity, to whom such information has been disclosed and
to recover all costs of pursuing such remedy, including reasonable attorneys’ fees, costs, and expenses. Nothing in this Agreement shall be construed as prohibiting Regeneration Technologies from pursuing other remedies as may be available to
it for the Executive’s breach or threatened breach, including recovery of damages from the Executive. The provisions of this Paragraph 8 shall survive the termination of Executive’s employment with Regeneration Technologies and the
termination of this Agreement. 
  
 9.    EXECUTIVE DEVELOPMENTS. 
  

The Executive is aware and understands that during the term of the Executive’s employment with Regeneration Technologies or with the financial and other assistance that may be
provided by Regeneration Technologies, the Executive may invent, create, develop, and improve certain valuable property such as, but not limited to, patents, trademarks, inventions, other patentable inventions and other trade secrets and formula
(“Employee Developments”). The Executive agrees that all Employee Developments that may be developed or produced by the Executive during the Executive’s employment by Regeneration Technologies are and will be the property of
Regeneration Technologies and that the Executive further agrees that he will, at the request of Regeneration Technologies, execute such documents Regeneration Technologies may reasonably request from time to time, to assign and transfer all of the
right, title and interest in Employee Developments that are the property of Regeneration Technologies to Regeneration Technologies and he will cooperate with Regeneration Technologies in connection with any patent applications. In this regard, the
Executive will, at all times, fully advise and inform Regeneration Technologies of all matters that the Executive may be developing or working on while employed by Regeneration Technologies. The Executive further agrees that upon the termination of
his or her employment with Regeneration Technologies for any reason whatsoever, the Executive shall immediately deliver and surrender to Regeneration Technologies any and all plans, documents and other materials of any nature relating to the
Employee Developments. Regeneration Technologies may provide additional compensation to the Executive as consideration for Employee Developments in accordance with any patent policy of Regeneration Technologies. The provisions of this Paragraph 9
shall survive the termination of Executive’s employment with Regeneration Technologies and the termination of this Agreement. 
  
 10.    NON-COMPETITION. 
  
 Executive recognizes that Regeneration Technologies, Inc.
possesses several valuable and legitimate business interests such as Confidential Information and Intellectual Property as defined in paragraph 6, above, substantial relationships with current or prospective customers, clients or vendors, and
customer, client or vendor goodwill associated with Regeneration Technologies, Inc. business. In recognition of these interests, the Executive’s exposure to these interests, in the event of the termination of the Executive’s employment
with
 
 

 Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K. Hutchison 
 Page
7 
  
 Regeneration Technologies either by Regeneration Technologies for cause or voluntarily by the Executive, the Executive agrees that for a period of
two (2) years following the effective date of the termination, the Executive will not engage in or be associated with or employed by any “Licensed Tissue Bank” organization, which engages in the business of recovery, procurement,
manufacturing, or distributing products from bone tissue in the United States. The Licensed Tissue Bank organizations that Executive specifically agrees not to become employed by or in any way associate with for a two (2) year period following the
effective date of Executive’s termination are as follows: Southeast Tissue Alliance, Inc. (University of Florida Tissue Bank), Tutogen Medical, Inc., Musculoskeletal Transplant Foundation; CryoLife; LifeCell; Allosource; Tissue Banks
International; Osteotech, Inc.; LifeLink Tissue Bank; Life Net; Community Tissue Services; American Red Cross; BioGenetics; and, Cryogenic. The Executive also agrees that for a two (2) year period following the effective date of Executive’s
termination not to participant in, assist with or in any way become associated with or employed by any new start up venture that the parties agree in advance is or will be engaged in the business of a Licensed Tissue Bank, or which Regeneration
Technologies, Inc., reasonably designates as a Licensed Tissue Bank. 
  
 This limitation of employment excludes any and all
non-biologic implantable medical devices. 
  
 In the event of the termination of the Executive’s employment with Regeneration
Technologies by Regeneration Technologies without cause, the Executive agrees that for a period of one (1) year following the effective date of such termination, the Executive will not engage in or be associated with or be employed by any
“Licensed Tissue Bank” organization, which engages in the business of recovery, procurement, manufacturing or distributing products from bone tissue within the United States. The Licensed Tissue Bank organizations that Executive
specifically agrees not to become employed by or associated with for a one (1) year period following the effective date of Executive’s termination without cause are as follows: Southeast Tissue Alliance, Inc. (University of Florida Tissue
Bank), Tutogen Medical, Inc., Bank Musculoskeletal Transplant Foundation; CryoLife; LifeCell; Allosource; Tissue Banks International; Osteotech, Inc.; LifeLink Tissue Bank; Life Net; Community Tissue Services; American Red Cross; BioGenetics; and,
Cryogenic. The Executive also agrees that for a one (1) year period following the effective date of Executive’s termination without cause not to participant in, assist with or in any way become associated with or employed by any new start up
venture that the parties agree in advance is or will be engaged in the business of a Licensed Tissue Bank. This limitation of employment excludes any and all non-biologic implantable medical devices. 
  
 The Executive acknowledges that this restrictive covenant is reasonably necessary to protect Regeneration Technologies’ legitimate business
interests, which are represented by, among other things, the substantial relationships between Regeneration Technologies and its licensees and tissue sources, as well as the goodwill established by Regeneration Technologies with licensees and tissue
sources in the United States and other countries where Regeneration Technologies’ tissues are distributed over a protracted period, specialized training, and other legitimate business reasons. 
  
 The Executive recognizes that Regeneration Technologies would not sign this Agreement without the inclusion of this covenant, and the Executive confirms
the sufficiency of the consideration received by the Executive, in the form of employment or continued employment by Regeneration Technologies, in accepting this covenant as a material term of this Agreement. The provisions of this Paragraph 10
shall survive the termination of Executive’s employment with Regeneration Technologies and the termination of this Agreement. 
 

  
 Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K. Hutchison 
 Page 8 
  
 11.    NON-SOLICITATION. 
  
 The Executive agrees during his or her employment with Regeneration Technologies, and for a period of two (2) years from the termination date of his or
her employment with Regeneration Technologies, not to: (a) solicit any employee of Regeneration Technologies, or any subsidiary or affiliate of Regeneration Technologies, or otherwise induce or attempt to induce any employee of Regeneration
Technologies to leave the employment of Regeneration Technologies; or (b) directly or indirectly attempt to solicit any client or customer of Regeneration Technologies, or any client or customer of any subsidiary or affiliate of Regeneration
Technologies, or directly or indirectly interfere with Regeneration Technologies’ relationship, or any subsidiary’s or affiliate’s relationship, with any of its clients or customers. The provisions of this Paragraph 11 shall survive
the termination of Executive’s employment with Regeneration Technologies and the termination of this Agreement. 
  
 12.    REMEDIES FOR BREACH OF LIMITATION OF EMPLOYMENT AND NON-SOLICITATION. 
  
 It is
understood and agreed by the Parties that Regeneration Technologies shall be entitled, upon application to a court of competent jurisdiction, to obtain injunctive relief to enforce the provisions of Paragraphs 10 and 11, which injunctive relief
shall be in addition to any other rights or remedies available to Regeneration Technologies. If such a violation occurs, the Executive shall be responsible for the payment of reasonable attorneys’ fees and other costs and expenses incurred by
Regeneration Technologies in enforcing the covenants contained in Paragraphs 10 and 11, whether incurred at the trial level or in any appellate proceeding. 
  
 13.    NON-DISPARAGEMENT. 
  
 While employed by Regeneration Technologies or any
affiliate of Regeneration Technologies and, provided Regeneration Technologies has complied with its obligations hereunder, after the Executive’s employment terminates for whatever reason, the Executive agrees not to disparage, denigrate, or
comment negatively upon, either orally or in writing, Regeneration Technologies, or any of its affiliates, officers, or directors, to or in the presence of any person or entity. 
  
 14.    INVALID PROVISION. 
  
 In the event any provision of this
Agreement should be or become invalid or unenforceable, the invalid provision shall not affect the validity and enforceability of any other provision of this Agreement. Similarly, if the scope of any restriction or covenant contained in this
Agreement should be or become too broad or extensive to permit enforcement of the covenant or provision to its full extent, then any restriction or covenant shall be enforced to the maximum extent permitted by law. The Executive consents and agrees
that the scope of any restriction or covenant may be modified accordingly in any judicial proceeding brought to enforce the restriction or covenant. 
  
 15.    ARBITRATION. 
  
 Any dispute or controversy arising under or in connection with
this Agreement shall be settled exclusively by arbitration conducted before a panel of three (3) arbitrators in the State of Florida in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the
arbitrator’s award in any court having jurisdiction. The Company shall bear the expense of any arbitration proceeding and shall reimburse Executive for all reasonable costs and expense, including reasonable attorneys’ fees and expenses, if
Executive is the prevailing party. 
 

  
 Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K. Hutchison 
 Page 9 
  
 16.    APPLICABLE LAW AND VENUE. 
  
 This Agreement shall be interpreted under and governed by the laws of the State of Florida, without regard to choice of law provisions. 

 
 17.    COMPLETE AGREEMENT. 
  
 The Executive acknowledges and agrees that no representation, promise, or agreement regarding the subject matter of this Agreement has been made to or with the Executive that is not provided for in this Agreement.
This Agreement represents the complete Agreement between Regeneration Technologies and the Executive regarding the subject matter of this Agreement. Any representations or agreements regarding the subject matter of this Agreement not explicitly
included in this Agreement are considered waived and/or merged into this Agreement, and are thus unenforceable. Any previous agreements between Regeneration Technologies and the Executive regarding the subject matter of this Agreement are superseded
by the execution of this Agreement, and shall lack any continuing force or effect. 
  
 19.    AMENDMENTS OR MODIFICATIONS.

  
 No amendments or modifications to this Agreement shall be binding on any of the Parties unless such amendment or
modification is in writing and executed by all of the Parties to this Agreement. 
  
 20.    SUCCESSORS AND ASSIGNS.

  
 This Agreement shall be binding upon and inure to the benefit of the Parties hereto, and, as to Executive, his legal heirs,
successors and assigns. 
  
 21.    CONSTRUCTION. 
  
 The Executive agrees and understands that the headings and captions of this Agreement are provided for convenience only and are intended to have no effect in construing or interpreting
this Agreement. The language in all parts of this Agreement shall be construed according to its fair meaning and not strictly for or against Regeneration Technologies or the Executive. 
  
 22.    NON-WAIVER. 
  
 The failure of Regeneration Technologies
or the Executive in any instance to exercise any right. power. or privilege under this Agreement or under law shall not constitute a waiver of any other right, power, or privilege. All waivers by either Regeneration Technologies or the Executive
must be contained in writing signed by the party to be charged, and in the case of Regeneration Technologies, by a member of the Board of Directors of Regeneration Technologies. 
  
 23.    READ AND UNDERSTAND. 
  
 The Parties to this Agreement
represent and agree that they have carefully read and fully understand all of the provisions of this Agreement and that they are entering into this Agreement with the intent to be bound by its terms and conditions. The Executive represents and
agrees that his initials on each page of this Agreement is irrefutable evidence that he has read and fully understands all of the provisions of this Agreement. 
 

  
 Employment Agreement Between Regeneration Technologies, Inc. and Mr. Brian K. Hutchison 
 Page 10 
  
 IN THE PRESENCE OF WITNESSES, the Parties execute this twenty (20) page
Agreement. 
  
 DATED this 30th day of November, 2001. 
  
  
 
	 Executive:
 	 	 On Behalf of REGENERATION
 TECHNOLOGIES, INC.:
 
	  	 	  
	 
	 /s/    BRIAN K. HUTCHISON
 
	 	 /s/    JAMIE M. GROOMS
 

	 Title: President and CEO
 	 	 Title: Chairman of the Board
 
	 Date: 12/6/01
 	 	 Date: 12/6/01
 
	  	 	  
	  	 	  
	  	 	  
	 Witness:
 	 	 Witness:
 
	 /s/    ILLEGIBLE
 
	 	 /s/    ILLEGIBLE
 

	 Date: 12/6/01
 	 	 Date: 12/6/01Prepared by R.R. Donnelley Financial -- Incentive Stock Option Grant Agreement

 Exhibit 10.37 
  
 REGENERATION TECHNOLOGIES, INC. 
  
 INCENTIVE STOCK OPTION GRANT AGREEMENT 
  
 KEY EMPLOYEES 
  
 This Grant
Agreement (the “Agreement”) is entered into this 3rd day of December, 2001 by and between REGENERATION TECHNOLOGIES, INC., a Delaware corporation (the “Corporation”), and Brian K. Hutchison
(“Grantee”), effective as of the Grant Date as defined in Article 1 hereof. 
  
 In consideration of the premises,
mutual covenants and agreements herein, the Corporation and the Grantee agree as follows: 
  
 ARTICLE 1 
 GRANT OF OPTION 
  
 Section 1.1    Grant of
Option.    The Corporation hereby grants to the Grantee, pursuant to the provisions of the Regeneration Technologies, Inc. Omnibus Stock Plan (the “Plan”), an incentive stock option to purchase shares of Common
Stock, par value of $0.00l per share, of the Corporation (“Stock”), subject to the provisions of this Agreement (the “Option”). Unless stated otherwise herein, capitalized terms in this Agreement shall have the same meaning
as defined in the Plan. Schedule A, attached hereto and incorporated herein, sets forth the following terms of the Option: 
  
 
	 
	 (i)
 	  	 the date the Administrator approved the Option (the “Grant Date”);
 
	 
	 (ii)
 	  	 the number of shares of Stock which the Grantee may purchase under the Option;
 
	 
	 (iii)
 	  	 the exercise price per share (the “Exercise Price”); and
 
	 
	 (iv)
 	  	 the date as of which the Option shall expire (the “Expiration Date”), at 5:00 p.m. Eastern Time, unless terminated earlier pursuant to other provisions of this
Agreement.
 

 
  
 Section 1.2    Limitation on Term of
Option.    Notwithstanding the foregoing, in no event shall the Option expire later than 5:00 p.m. Eastern Time on the day prior to the tenth (10th) anniversary of its Grant Date (or on the day prior to the fifth (5th)
anniversary of its Grant Date if the Grantee owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Corporation or of any of its subsidiaries on the Grant Date). 
  
 ARTICLE 2 
 VESTING 
  
 Section 2.1    Vesting Schedule.    Unless the Option terminates earlier pursuant to other provisions of this Agreement, the Option
shall vest and become exercisable as provided in the following schedule: 
  
 Percentage of the Option

 Vested and Exerciseable            As of 
  
 
	 0%
 	    	 Any date prior to the first anniversary of the Grant Date.
 
	 
	 20%
 	    	 Any date on or after the first anniversary of the Grant Date.
 
	 
	 40%
 	    	 Any date on or after the second anniversary of the Grant Date
 
	 
	 60%
 	    	 Any date on or after the third anniversary of the Grant Date
 
	 
	 80%
 	    	 Any date on or after the fourth anniversary of the Grant Date
 
	 
	 100%
 	    	 Any date on or after the fifth anniversary of the Grant Date
 

 

  
 Section 2.2    Acceleration of
Vesting.    Unless the Option has earlier terminated pursuant to the provision of the Agreement, vesting of the Option shall be accelerated so that all unvested shares of Stock subject to the Option shall become one
hundred percent (100%) vested in the Grantee upon a Change of Control. For purposes of this Agreement, the term “Change of Control” shall mean (i) the sale of all or substantially all of the assets of the Corporation, (ii) the sale of more
than fifty percent (50%) of the outstanding common stock of the Corporation in a non-public sale, (iii) the dissolution or liquidation of the Corporation, or (iv) any merger, share exchange, consolidation or other reorganization or business
combination of the Corporation if immediately after such transaction either (A) persons who were directors of the Corporation immediately prior to such transaction do not constitute at least a majority of the directors of the surviving entity, or
(B) persons who hold a majority of the voting capital stock of the surviving entity are not persons who held a majority of the voting capital stock of the Corporation immediately prior to such transaction. 
  
 ARTICLE 3 
 EXERCISE OF OPTION 
  
 Section 3.1:    Exercisability of Option.    The Option is exercisable only if it is vested and
has not been terminated. If exercisable, the Option may be exercised in whole or in part, subject to the conditions precedent described in Section 3.3. Only Grantee and, after his death, his executor, personal representative, or the person to whom
the Option shall have been transferred by will or the laws of descent and distribution, may exercise the Option. 
  
 Section
3.2:    Manner of Exercise.    Grantee or any other person exercising the Option may do so only by delivering written notice thereof to the Administrator. Such notice shall be in the form as attached
hereto, unless the Administrator requires otherwise. Notwithstanding the foregoing, the Option may not be exercised at any one time as to fewer than five (5) Shares or, if less, such number of Shares as to which the Option is then exercisable. Such
notice shall be accompanied by full payment of the Exercise Price. Payment of the Exercise Price shall be made in cash, provided that the Administrator may authorize a payment of the Exercise Price to be 
 made, in whole or in part, by such other means as the Administrator may prescribe at the time of exercise. The Option may be exercised only in multiples of whole Shares and no fractional Shares shall be issued. If the
Common Stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended, the Exercise Price may be paid, in whole or in part, subject to such limitations as the Administrator may determine, by delivery of a properly executed
exercise notice, together with irrevocable instructions: (i) to a brokerage firm designated by the person exercising the Option and approved by the Administrator to deliver promptly to the Corporation the aggregate amount of sale or loan proceeds to
pay the Exercise Price and any withholding tax obligations that may arise in connection with the exercise, and (ii) to the Corporation to deliver the certificates for such purchased Shares directly to such brokerage firm. 
  
 Section 3.3:    Issuance of Shares upon Exercise.    Upon exercise of the Option and payment of
the Exercise Price, the Corporation shall issue to Grantee the number of Shares so paid for, in the form of fully paid and nonassessable Common Stock. If the Common Stock is not yet registered under Section 12 of the Securities Exchange Act of 1934,
as amended, the Grantee shall be required to execute and deliver, as a condition precedent to the exercise of the option and the issuance of the Shares to the Grantee, a stockholder agreement and/or stock restriction agreement which shall contain
certain stock restrictions, including but not limited to a waiver of inspection rights, proxy voting, limitations on transfer and other restrictions. The Grantee’s stock certificates shall be held in escrow by the Corporation during the period
that the shares are subject to restriction. The stock certificates for any Shares issued hereunder shall, unless such Shares are registered, bear a legend restricting transferability of such Shares and referencing the stockholder agreement and stock
restriction agreement. 
 

 -2- 

  
 ARTICLE 4 
 TERMINATION
OF OPTION 
  
 Section 4.1    Termination, In General.    The Option
granted hereby shall terminate and be of no force or effect after the Expiration Date set forth on Schedule A, unless terminated prior to such time as provided below. Notwithstanding anything contained herein, vesting of the Option pursuant to
Section 2.1 shall cease upon the Grantee’s termination of employment by, or service to, the Corporation, unless otherwise agreed by the Corporation in writing. 
  
 Section 4.2    Termination of Employment or Service or for Reason Other Than Death or Disability.    Unless the Option has earlier
terminated pursuant to the provisions of the Agreement, the Option shall terminate in its entirety, regardless of whether the Option is vested in whole or in part, thirty (30) days after the date the Grantee is no longer employed by, or not in the
service of, the Corporation and its Affiliates for any reason other than the Grantee’s death or Disability. Notwithstanding the foregoing, the Option shall terminate in its entirety, regardless of whether the Option is vested in whole or in
part, upon termination of the employment or service of the Grantee by the Corporation or an Affiliate for “Cause”. 
  
 If
the Grantee is a party to a written employment agreement or service agreement with the Corporation or an Affiliate then currently in effect which contains a definition of “cause”, “termination for cause” or words of similar
import, whether such Grantee is terminated for “Cause” pursuant to this Section 4.2 shall be determined according to the terms of and in a manner consistent with the provisions of such written agreement. If the Grantee is not party to such
a written employment agreement or service agreement with the Corporation or an Affiliate, then for purposes of this Section 4.2, “Cause” shall mean (a) the conviction of the Grantee of, or the entry of a pleading of guilty or nolo
contendere by the Grantee to, any felony or any crime involving moral turpitude, (b) willful misconduct in connection with the Grantee’s duties, willful failure to follow the directions of the Grantee’s supervisor or supervisors, or
willful failure to perform his or her responsibilities in the best interest of the Corporation, except in cases involving the mental or physical incapacity or disability of the Grantee, or (c) in the sole judgment of the President of the
Corporation, the Grantee has acted or is acting in a manner that is not in the best interest of the Corporation or its employees, including but not limited to, disparaging the Corporation or its products or engaging in harassment or other
inappropriate behavior directed towards employees of the Corporation. “Willful misconduct” and “willful failure to perform” shall not include actions or inactions on the part of the Grantee which were taken or not taken in good
faith by the Grantee. The good faith determination by the Administrator of whether the Grantee’s employment or service was terminated by the Corporation for “Cause” shall be final and binding for all purposes hereunder. 

 
 Section 4.3    Upon Grantee’s Death.    Unless the Option has earlier terminated
pursuant to the provisions of the Agreement, upon the Grantee’s death the Grantee’s executor, personal representative, or the person(s) to whom the Option shall have been transferred by will or the laws of descent and distribution, may
exercise all or any part of the outstanding Option with respect to the shares of Stock as to which the Option is vested as of the Grantee’s date of death, provided such exercise occurs within six (6) months after the date of the Grantee’s
death, but not later than the Expiration Date of the Option. Unless sooner terminated, the Option shall terminate upon the expiration of such six (6) month period. 
  
 Section 4.4    Termination of Employment or Service by Reason of Disability.    Unless the Option has earlier terminated pursuant to
the provisions of the Agreement, in the event that the Grantee ceases, by reason of Disability, to be an employee of or in the service of the Corporation or an Affiliate, the outstanding Option may be exercised in whole or in part with respect to
the shares of Stock as to which the Option is vested as of the date of the Grantee’s termination of employment or service due to Disability at any time within six (6) months after the date of such termination, but not later than the Expiration
Date of the Option. Unless sooner terminated, the Option shall terminate upon the expiration of such six (6) month period. 
 

 -3- 

  
 For purposes of this Agreement, Disability shall mean the inability to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months.
The Administrator may require such proof of Disability as the Administrator in its sole discretion deems appropriate and the Administrator’s determination as to whether the Grantee is Disabled shall be final and binding on all parties
concerned. 
  
 Section 4.5    Leave of Absence.    For purposes of this
Agreement, the Grantee’s employment or service with the Corporation or an Affiliate shall not be deemed to terminate if the Grantee takes any military leave, sick leave, or other bona fide leave of absence approved by the Administrator of
ninety (90) days or less. In the event of a leave in excess of ninety (90) days, the Grantee’s employment or service shall be deemed to terminate on the ninety-first (91st) 
 day of the
leave unless the Grantee’s right to re-employment with the Corporation or Affiliate remains guaranteed by statute or contract. Notwithstanding the foregoing, unless otherwise determined by the Administrator (or required by law), a leave of
absence shall not be treated as employment or service for purposes of vesting in additional shares of Stock during such leave pursuant to Section 2.1 of this Agreement. 
  
 ARTICLE 5 
 ADJUSTMENTS; BUSINESS COMBINATIONS 
  
 Section 5.1    Adjustments for Events Affecting Common Stock.    In the event of changes in the Common Stock of the Corporation by
reason of any stock dividend, split-up, recapitalization, merger, consolidation, business combination or exchange of shares and the like, the Administrator shall, in its discretion, make appropriate adjustments to the number, kind and price of
shares covered by this Option, and shall, in its discretion and without the consent of the Grantee, make any other adjustments in this Option, including but not limited to reducing the number of shares subject to the Option or providing or mandating
alternative settlement methods such as settlement of the Option in cash or in shares of Common Stock or other securities of the Corporation or of any other entity, or in any other matters which relate to the Option as the Administrator shall, in its
sole discretion, determine to be necessary or appropriate. 
  
 Section 5.2    Pooling of Interests
Transaction.    Notwithstanding anything in the Plan or this Agreement to the contrary and without the consent of the Grantee, the Administrator, in its sole discretion, may make any modifications to the Option, including
but not limited to cancellation, forfeiture, surrender or other termination of the Option in whole or in part regardless of the vested status of the Option, in order to facilitate any business combination that is authorized by the Board to comply
with requirements for treatment as a pooling of interests transaction for accounting purposes under generally accepted accounting principles. 
  
 Section 5.3    Adjustments for Unusual Events.    The Administrator is authorized to make, in its discretion and without the consent of the Grantee, adjustments in
the terms and conditions of, and the criteria included in, the Option in recognition of unusual or nonrecurring events affecting the Corporation, or the financial statements of the Corporation or any Subsidiary, or of changes in applicable laws,
regulations, or accounting principles, whenever the Administrator determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Option or
the Plan. 
  
 Section 5.4    Binding Nature of Adjustments.    Adjustments
under this Article 5 will be made by the Administrator, whose determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued pursuant to this Option on
account of any such adjustments. 
 

 -4- 

 ARTICLE 6 
 MISCELLANEOUS 
  
 Section 6.1    Non-Guarantee of Employment.    Nothing in the Plan or this Agreement shall alter
the employment status of the Grantee, nor be construed as a contract of employment between the Corporation (or an Affiliate) and the Grantee, or as a contractual right of the Grantee to continue in the employ or service of the Corporation (or an
Affiliate), or as a limitation of the right of the Corporation (or an Affiliate) to discharge the Grantee at any time with or without cause or notice. 
  
 Section 6.2    No Rights of Stockholder.    The Grantee shall not have any of the rights of a stockholder with respect to the shares of Stock that may be issued
upon the exercise of the Option until such shares of Stock have been issued upon the due exercise of the Option, subject to and in accordance with the provisions of Section 3.3. No adjustment shall be made for dividends or distributions or other
rights for which the record date is prior to the date such certificate or certificates are issued. 
  
 Section
6.3    Nature of Option.    The Option is intended to be a stock option that qualifies as an incentive stock option (“Incentive Stock Option”) within the meaning of Section 422 of the
Internal Revenue Code of 1986, as amended, to the fullest extent permitted within the limit set forth under Section 422(d) of the Code, and this Agreement shall be so construed. The aggregate fair market value (determined as of the Grant Date) of
the shares of Stock with respect to which all Incentive Stock Options first become exercisable by the Grantee in any calendar year under the Plan or any other plan of the Corporation (and its parent and subsidiary corporations, as may exist from
time to time) may not exceed $100,000 or such other amount as may be permitted from time to time under Section 422 of the Code. To the extent that such aggregated fair market value shall exceed $100,000 or other applicable amount in any calendar
year, such stock options shall be treated as nonqualified stock options with respect to the amount of the aggregate fair market value thereof that exceeds the Section 422(d) limit. For this purpose, the Incentive Stock Options will be taken into
account in the order in which they were granted. In such case, the Corporation may designate the shares of Stock that are to be treated as stock acquired pursuant to a nonqualified stock option by issuing separate certificates for such shares and
identifying the certificates as such in the stock transfer records of the Corporation. 
  
 Section
6.4    Notice of Disqualifying Disposition.    If the Grantee makes a disposition (as that term is defined in Section 424(c) of the Code) of any shares of Stock acquired pursuant to the exercise
of this Option within two (2) years of the Grant Date or within one (1) year after the shares of Stock are transferred to the Grantee, the Grantee shall notify the Administrator of such disposition in writing within thirty (30) days of the
disposition. 
  
 Section 6.5    The Corporation’s Rights.    The
existence of this Option shall not affect in any way the right or power of the Corporation or its stockholders to make or authorize any or all adjustments, recapitalizations, reorganizations or other changes in the Corporation’s capital
structure or its business, or any merger or consolidation of the Corporation, or any issue of bonds, debentures, preferred or other stocks with preference ahead of or convertible into, or otherwise affecting the Stock or the rights thereof, or the
dissolution or liquidation of the Corporation, or any sale or transfer of all or any part of the Corporation’s assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. 
  
 Section 6.6    Withholding of Taxes.    The Corporation or any Affiliate shall have the right to
deduct from any compensation or any other payment of any kind (including withholding the issuance of shares of Stock) due the Grantee the amount of any foreign, federal, state or local taxes required by law to be withheld as the result of the
exercise of the Option or the lapsing of any restriction with respect to any shares of Stock acquired on exercise of the Option; provided, however, that the value of the shares of Stock withheld may not exceed the statutory minimum withholding
amount required by law. In lieu of such deduction, the Administrator may
 
 

 -5- 

 
require the Grantee to make a cash payment to the Corporation or an Affiliate, equal to the amount required to be withheld. If the Grantee does not make such payment when requested, the
Corporation may refuse to issue any Stock certificate under the Plan until arrangements satisfactory to the Administrator for such payment have been made. 
  
 Section 6.7    Grantee.    Whenever the word “Grantee” is used in any provision of this Agreement under circumstances where the provision should
logically be construed to apply to the estate, personal representative or beneficiary to whom this Option may be transferred by will or by the laws of descent and distribution, the word “Grantee” shall be deemed to include such person.

  
 Section 6.8    Nontransferability of Option.    The Option shall be
nontransferable otherwise than by will or the laws of descent and distribution and during the lifetime of the Grantee, the Option may be exercised only by the Grantee or, during the period the Grantee is under a legal disability, by the
Grantee’s guardian or legal representative. Except as provided in the preceding sentence, the Option may not be assigned, transferred, pledged, hypothecated or disposed of in any way (whether by operation of law or otherwise) and shall not be
subject to execution, attachment or similar process. 
  
 Section
6.9    Notices.    All notices and other communications made or given pursuant to the Agreement shall be in writing and shall be sufficiently made or given if hand delivered or mailed by certified
mail, addressed to the Grantee at the address contained in the records of the Corporation, or addressed to the Administrator, care of the Corporation for the attention of its Secretary at its principal office or, if the receiving party consents in
advance, transmitted and received via telecopy or via such other electronic transmission mechanism as may be available to the parties. 
  
 Section 6.10    Entire Agreement; Modification.    This Agreement contains the entire agreement between the parties with respect to the subject matter contained herein and may not be
modified, except as provided in the Plan or in a written document signed by each of the parties hereto. Any oral or written agreements, representations, warranties, written inducements, or other communications made prior to the execution of the
Agreement shall be void and ineffective for all purposes. 
  
 Section 6.11    Conformity with
Plan.    This Agreement is intended to conform in all respects with, and is subject to all applicable provisions of, the Plan, which is incorporated herein by reference. Inconsistencies between this Agreement and the Plan
shall be resolved in accordance with the terms of the Plan. In the event of any ambiguity in the Agreement or any matters as to which the Agreement is silent, the Plan shall govern. A copy of the Plan is available upon request to the Administrator.

  
 Section 6.12    Governing Law.    This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, other than the conflict of laws principles thereof. 
  
 Section 6.13    Headings.    The headings in the Agreement are for reference purposes only and shall not affect the meaning or interpretation of the Agreement. 
  
 [signatures on next page] 
 

 -6- 

  
  
 IN WITNESS WHEREOF, the Corporation has caused this
Agreement, which shall be effective as of the Grant Date, to be executed by its duly authorized officer, and the Grantee has hereunto set his hand and seal. 
  
 
	 ATTEST:
 	 	 REGENERATION TECHNOLOGIES, INC.
 
	 
	 

 	 	  	 	 By:

        
 
	  	  	  	 	  	 	 Jamie M. Grooms, President/CEO
 
	 
	  	  	  	 	  	 	                     Date:
12/6/01                    
 

 
  
  
 
	 WITNESS:
 	    	 GRANTEE
 
	 
	 

 	    	 

 
	  	  	  	    	  	  	 Name Brian K. Hutchison
 
	 
	  	  	  	    	  	  	 Date:
12/6/01                                       
     
 
	 
	  	  	  	    	  	  	 SSN:  (Required) ###-##-####             
 

 
 

 -7- 

 SCHEDULE A 
  
 OF
REGENERATION TECHNOLOGIES, INC. 
  
 INCENTIVE STOCK OPTION GRANT AGREEMENT 
  

 
 
	 Name of Grantee:
 	  	 Brian K. Hutchison
 
	 
	 Date Option Was Approved By Plan Administrator:
 	  	 12/3/2001
 
	 
	 Number of Shares:
 	  	 500,000 shares of Regeneration     Technologies, Inc. Common Stock
 
	 
	 Exercise Price Per Share:
 	  	 $10.13 per share
 
	 
	 Expiration Date:
 	  	 12/3/2011
 

 
 

 -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]